On August 2, 2021 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported its participation in a panel discussion at the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021 (Press release, Ideaya Biosciences, AUG 2, 2021, View Source [SID1234585558]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2021 Wedbush PacGrow Healthcare Virtual Conference
"Synthetic Lethal (Weapon)" panel discussion Tuesday, August 10, 2021 at 11:30 am ET
Panelists include:

Michael Dillon, Senior Vice President and Chief Scientific Officer, Head of Research, IDEAYA Biosciences
Markus Renschler, President and CEO, Cyteir Therapeutics
Vatnak Vat-Ho, CBO, Ryvu Therapeutics
Barbara Weber, Chief Executive Officer, Tango Therapeutics
A live audio webcast of the event will be available by visiting the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at View Source A replay of the webcast will be available for 30 days following the live event.